Literature DB >> 14583335

Acute angiotensin II increases plasma F2-isoprostanes in salt-replete human hypertensives.

Laine J Murphey1, Jason D Morrow, Pairunyar Sawathiparnich, Gordon H Williams, Douglas E Vaughan, Nancy J Brown.   

Abstract

Angiotensin (Ang) II induces oxidative stress in vitro and in animal models of hypertension. We tested the hypothesis that Ang II increases oxidative stress in human hypertension, as assessed by plasma F2-isoprostane concentrations. Plasma F2-isoprostanes, hemodynamic and endocrine parameters were measured at baseline and following a 55 min infusion of 3 ng/kg/min Ang II in 13 normotensive and 13 hypertensive volunteers ingesting a high- (200 mmol/d) or low- (10 mmol/d) sodium diet. Mean arterial pressure (MAP) and body mass index were higher in hypertensive subjects. Ang II infusion increased MAP (p<.001) and plasma aldosterone concentrations (p<.001) and decreased plasma renin activity (p<.001) and renal plasma flow (p<.001) to a similar extent in both groups. Plasma F2-isoprostane concentrations were similar at baseline. There was no effect of Ang II on F2-isoprostane concentrations during low-salt intake in either group (normotensive 51.7 +/- 7.1 to 53.7 +/- 6.5 pg/ml and hypertensive 52.2 +/- 8.2 to 56.2 +/- 10.0 pg/ml; mean +/- SE). During high-salt intake, Ang II increased F2-isoprostane concentrations in the hypertensive group (52.3 +/- 7.2 to 63.2 +/- 10.4 pg/ml, p=0.010) but not in the normotensive group (54.2 +/- 4.4 to 58.9 +/- 6.6 pg/ml, p=0.83). Acute Ang II infusion increases oxidative stress in vivo in hypertensive humans. The renin-angiotensin system may contribute to oxidative stress in human cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14583335     DOI: 10.1016/s0891-5849(03)00395-2

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  7 in total

Review 1.  Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean?

Authors:  Barry Halliwell; Matthew Whiteman
Journal:  Br J Pharmacol       Date:  2004-05       Impact factor: 8.739

2.  Role of superoxide and thromboxane receptors in acute angiotensin II-induced vasoconstriction of rabbit vessels.

Authors:  Sandra L Pfister; Kasem Nithipatikom; William B Campbell
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-04-01       Impact factor: 4.733

3.  Renin-angiotensin system activation correlates with microvascular dysfunction in a prospective cohort study of clinical sepsis.

Authors:  Kevin C Doerschug; Angela S Delsing; Gregory A Schmidt; Alix Ashare
Journal:  Crit Care       Date:  2010-02-22       Impact factor: 9.097

Review 4.  Ischemia and reactive oxygen species in sympathetic hyperactivity states: a vicious cycle that can be interrupted by renal denervation?

Authors:  Lisette E G Hubens; Willemien L Verloop; Jaap A Joles; Peter J Blankestijn; Michiel Voskuil
Journal:  Curr Hypertens Rep       Date:  2013-08       Impact factor: 5.369

5.  Intrarenal dopamine inhibits progression of diabetic nephropathy.

Authors:  Ming-Zhi Zhang; Bing Yao; Shilin Yang; Haichun Yang; Suwan Wang; Xiaofeng Fan; Huiyong Yin; Agnes B Fogo; Gilbert W Moeckel; Raymond C Harris
Journal:  Diabetes       Date:  2012-06-11       Impact factor: 9.461

6.  Effect of high-altitude trekking on blood pressure and on asymmetric dimethylarginine and isoprostane production: Results from a Mount Ararat expedition.

Authors:  Vittore Verratti; Claudio Ferrante; Davide Soranna; Antonella Zambon; Suwas Bhandari; Giustino Orlando; Luigi Brunetti; Gianfranco Parati
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-08-06       Impact factor: 3.738

7.  Inflammatory cytokines and plasma redox status responses in hypertensive subjects after heat exposure.

Authors:  S F Fonseca; V A Mendonça; M C Teles; V G C Ribeiro; R Tossige-Gomes; C D C Neves; E Rocha-Vieira; L H R Leite; D D Soares; C C Coimbra; A C R Lacerda
Journal:  Braz J Med Biol Res       Date:  2016-02-02       Impact factor: 2.590

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.